Journal: Chemical Engineering Journal

Article Title: A tumor-responsive nanostrategy for reducing the risk of immunotherapy-related myocarditis

doi: 10.1016/j.cej.2024.153131

Figure Lengend Snippet: Fig. 1. Schematic and characterization of anti-PD1/CTLA4@MSA. (a-b) Schematic illustration for the preparation and function of anti-PD1/CTLA4@MSA; (c) Incorporation efficacy of anti-PD1/CTLA4@MSA by gel electrophoresis assays; (d) Hydrodynamic distributions of anti-PD1/CTLA4@MSA in the absence (black line) and presence of H2O2 (red line) measured by DLS; (e) TEM image of anti-PD1/CTLA4@MSA in the absence and presence of H2O2, scale bar: 200 nm; (f) Talos STEM images of anti-PD1/CTLA4@MSA (Ca labeled, red channel; Gd labeled, blue channel), scale bar: 200 nm; (g) Quantified anti-CTLA4 release from anti-PD1/ CTLA4@MSA in the presence of different concentration of H2O2 using ELISA kit; (h) Quantified anti-PD1 release from anti-PD1/CTLA4@MSA in the presence of different concentration of H2O2 using ELISA kit. (For interpretation of the references to colour in this figure legend, the reader is referred to the web version of this article.)

Article Snippet: Anti-CTLA4 antibody (cat. # HY-P99132) was purchased from MedChemExpress.

Techniques: Nucleic Acid Electrophoresis, Labeling, Concentration Assay, Enzyme-linked Immunosorbent Assay

Journal: Chemical Engineering Journal

Article Title: A tumor-responsive nanostrategy for reducing the risk of immunotherapy-related myocarditis

doi: 10.1016/j.cej.2024.153131

Figure Lengend Snippet: Fig. 2. Tumor-targeted fluorescence labeling and biodistribution analysis of anti-PD1/CTLA4@MSA. (a) In vivo time-dependent fluorescence imaging at different channels. The excitation and emission wavelengths of ICG are 710 and 800 nm, and the excitation and emission wavelengths of MB are 640 and 700 nm, respectively. For FRET channel, the excitation wavelength of MB and emission wavelength of ICG were used; (b) Region-of-interest analysis of fluorescent signals of FRET; (c) The in vivo intensity ratio of ICG/MB; (d) Fluorescence imaging of organs from mice treated with Cy5-loaded MSA, anti-CTLA4, anti-PD1, anti- CTLA4@MSA, anti-PD1@MSA and anti-PD1/CTLA4@MSA; (e) Ratio of fluorescence intensity to MSA in major organs; (f) Region-of-interest analysis of fluores cent signals from organs; Data are presented as mean ± SD. P values were calculated using a t-test.

Article Snippet: Anti-CTLA4 antibody (cat. # HY-P99132) was purchased from MedChemExpress.

Techniques: Fluorescence, Labeling, In Vivo, Imaging

Journal: Chemical Engineering Journal

Article Title: A tumor-responsive nanostrategy for reducing the risk of immunotherapy-related myocarditis

doi: 10.1016/j.cej.2024.153131

Figure Lengend Snippet: Fig. 3. Echocardiography of anti-PD1/CTLA4@MSA on ICIs-related myocarditis. (a) Schematic illustration of BALB/c mice treated process. Six groups (n = 5 in each group): Control; EAM; EAM with anti-CTLA4 (100 μg/mouse/2 d) treatment; EAM with anti-PD1 (100 μg/mouse/2 d) treatment; EAM with anti-PD1 (50 μg/ mouse/2 d) and anti- CTLA4 (50 μg/mouse/2 d) treatment; EAM with anti-PD1/CTLA4@MSA (100 μg/mouse/2 d) treatment; (b) Representative images of thoracic echocardiography; (c) Quantifications of ejection fraction and fraction shortening. The data were expressed as mean ± SD. P values were calculated using a t-test.

Article Snippet: Anti-CTLA4 antibody (cat. # HY-P99132) was purchased from MedChemExpress.

Techniques: Control

Journal: Chemical Engineering Journal

Article Title: A tumor-responsive nanostrategy for reducing the risk of immunotherapy-related myocarditis

doi: 10.1016/j.cej.2024.153131

Figure Lengend Snippet: Fig. 5. Biosafety evaluation of anti-PD1/CTLA4@MSA. (a) The representa tive images of H&E stained heart, liver, spleen, lung, and kidney sections in mice with different treatments, scale bar: 500 μm; (b-e) The levels of serum creatinine (CRE), blood urea nitrogen (BUN), alanine transaminase (ALT), and aspartate aminotransferase (AST) analyzed by ELISA assays. Data are presented as mean ± SD.

Article Snippet: Anti-CTLA4 antibody (cat. # HY-P99132) was purchased from MedChemExpress.

Techniques: Staining, Enzyme-linked Immunosorbent Assay

Journal: Chemical Engineering Journal

Article Title: A tumor-responsive nanostrategy for reducing the risk of immunotherapy-related myocarditis

doi: 10.1016/j.cej.2024.153131

Figure Lengend Snippet: Fig. 4. Effect of anti-PD1/CTLA4@MSA on ICIs-related myocarditis in myocardial inflammation and fibrosis. Representative images of H&E (a) and Masson staining (b); (c-g) Serum levels of creatine kinase (CK), creatine kinase-MB (CK-MB), lactate dehydrogenase-1 (LDH-1), cardiac troponin T (cTnT), and cardiac troponin I (cTnI). The data were expressed as mean ± SD. P values were calculated using a t-test.

Article Snippet: Anti-CTLA4 antibody (cat. # HY-P99132) was purchased from MedChemExpress.

Techniques: Staining

Journal: Chemical Engineering Journal

Article Title: A tumor-responsive nanostrategy for reducing the risk of immunotherapy-related myocarditis

doi: 10.1016/j.cej.2024.153131

Figure Lengend Snippet: Fig. 6. Anti-tumor efficacy of anti-PD1/CTLA4@MSA. (a) Tumor growth curve of volume according to time during different administrations (n = 5); (b) Pho tographs and weight of tumors from mice during different administrations after 17-day (n = 5); (c) Ki-67 staining and the percentage of Ki-67 positive cells in xenograft tumors measured by optical microscopes, scale bar: 100 μm. Data are presented as mean ± SD. P values were calculated using a t-test.

Article Snippet: Anti-CTLA4 antibody (cat. # HY-P99132) was purchased from MedChemExpress.

Techniques: Staining

Journal: Chemical Engineering Journal

Article Title: A tumor-responsive nanostrategy for reducing the risk of immunotherapy-related myocarditis

doi: 10.1016/j.cej.2024.153131

Figure Lengend Snippet: Fig. 7. Immune cell infiltration of anti-PD1/CTLA4@MSA. (a-b) Flow cytometry analysis and percentage of CD8+ T cells in CD45+/CD3+ T cells in tumors from mice with different treatments; (c-d) Flow cytometry analysis and percentage of Treg cells in CD25+/CD4+ T cells in tumors from mice with different treatments; (e- g) Immunofluorescence images of CD8+ T cells and Treg cells in tumor sections with the indicated treatments, scale bar: 50 μm; (h-j) The content of Granzyme B, TNF-α, and IFN-γin xenograft tumors from mice with different treatments analyzed by immunofluorescence and ELISA assays. Data are presented as mean ± SD. P values were calculated using a t-test.

Article Snippet: Anti-CTLA4 antibody (cat. # HY-P99132) was purchased from MedChemExpress.

Techniques: Flow Cytometry, Immunofluorescence, Enzyme-linked Immunosorbent Assay

Journal: PLoS ONE

Article Title: Characterization of the Leukocyte Response in Acute Vocal Fold Injury

doi: 10.1371/journal.pone.0139260

Figure Lengend Snippet: Monoclonal anti-pig specific antibodies and their labels.

Article Snippet: The following conjugated anti-pig antibodies were also used simultaneously: CD14 or SWC3 (myeloid cells) labeled to fluorescein isothiocyanate (FITC; Abd Serotec) and human CD152 (CTLA–4) fused to murine IgG2a Fc labeled with RPE (Ancell Corporation, Stillwater, MN), which denotes expression of co-stimulatory markers CD80 and CD86.

Techniques: Labeling

Journal: CPT: Pharmacometrics & Systems Pharmacology

Article Title: Quantitative systems pharmacology modeling provides insight into inter‐mouse variability of Anti‐CTLA4 response

doi: 10.1002/psp4.12800

Figure Lengend Snippet: Structure of anti‐CTLA4 quantitative system pharmacology (QSP) model developed to capture the response variability in CT26 tumor volume profiles. (a) Schematics of the QSP model. Act CD8, activated CD8+ T cell; Inact CD8, inactive CD8+ T cell; Prolif CD8, proliferating CD8+ T cell; CTL, cytotoxic T lymphocyte; TC, tumor cell; TCd, damaged tumor cell; Treg, regulatory T cell. (b) Individual tumor volume profiles in CT26 syngeneic mice in response to anti‐CTLA4 antibody 9H10 treatment given introvenously Q3dx3. (c) Number of mice exhibiting progressive disease (PD), partial response (PR), and complete response (CR) per dose group

Article Snippet: Mice were treated with phosphate–buffered saline (PBS, control) or anti‐mouse CTLA4 antibody (BioXell clone 9H10) given at 0.625, 1.25, 2.5, 5, or 10 mg/kg intravenously every 3 days for a total of three doses (Q3dx3) ( n = 10/group).

Techniques:

Journal: CPT: Pharmacometrics & Systems Pharmacology

Article Title: Quantitative systems pharmacology modeling provides insight into inter‐mouse variability of Anti‐CTLA4 response

doi: 10.1002/psp4.12800

Figure Lengend Snippet: Anti‐CTLA4 model parameters

Article Snippet: Mice were treated with phosphate–buffered saline (PBS, control) or anti‐mouse CTLA4 antibody (BioXell clone 9H10) given at 0.625, 1.25, 2.5, 5, or 10 mg/kg intravenously every 3 days for a total of three doses (Q3dx3) ( n = 10/group).

Techniques: Concentration Assay, Clinical Proteomics, Membrane, Binding Assay, Activation Assay

Journal: CPT: Pharmacometrics & Systems Pharmacology

Article Title: Quantitative systems pharmacology modeling provides insight into inter‐mouse variability of Anti‐CTLA4 response

doi: 10.1002/psp4.12800

Figure Lengend Snippet: Fitted parameter values for the anti‐CTLA4 NLME QSP model

Article Snippet: Mice were treated with phosphate–buffered saline (PBS, control) or anti‐mouse CTLA4 antibody (BioXell clone 9H10) given at 0.625, 1.25, 2.5, 5, or 10 mg/kg intravenously every 3 days for a total of three doses (Q3dx3) ( n = 10/group).

Techniques: Activation Assay, Standard Deviation